Physician profile
Xiaohui Lu
NPI 1619022464
$2,626.30
in general payments reported to CMS, 2019-2025
28 companies · $353 in 2025
The $353 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $641 · 2020: $95.88 · 2021: $26.55 · 2022: $571 · 2023: $517 · 2024: $422 · 2025: $353.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,292.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,291.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $460.57 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $363.47 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $219.52 | 2019-2024 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $215.83 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $151.43 | 2022-2025 | |
| Glaxosmithkline, LLC. | $147.46 | 2019-2024 | Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $135.32 | 2019-2020 | |
| Amgen INC. | $101.66 | 2019-2023 | Repatha |
| Sanofi-Aventis U.S. LLC | $87.39 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $83.47 | 2022 | |
| Pfizer INC. | $69.14 | 2019-2023 | |
| Optinose US, INC. | $60.95 | 2019-2020 | |
| Abbott Laboratories | $59.84 | 2022-2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $56.99 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $54.38 | 2025 | Veozah |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $53.50 | 2024 | |
| Dexcom, INC. | $41.44 | 2024-2025 | Dexcom G6 Transmitter |
| Seqirus USA INC | $33.42 | 2024-2025 | Fluad, Flucelvax |
| Vbi Vaccine (Delaware) INC. | $31.87 | 2022-2023 | Prehevbrio |
| Boston Scientific Corporation | $31.41 | 2025 | Wavewriter Alpha Prime 16 |
| Abbvie INC. | $28.79 | 2019 | |
| Janssen Pharmaceuticals, INC | $26.98 | 2019-2020 | |
| Inogen, INC. | $22.94 | 2025 | |
| Medtronic, INC. | $22.06 | 2022 | |
| Amarin Pharma, INC. | $20.33 | 2019 | |
| Idorsia Pharmaceuticals US INC | $17.49 | 2023 | Quviviq |
| Genentech USA, INC. | $15.53 | 2019 | |
| Insulet Corporation | $13.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xiaohui Lu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.